头孢噻利和头孢哌酮舒巴坦治疗中重度肺部细菌感染的临床效果分析

摘要

目的分析头孢噻利和头孢哌酮舒巴坦治疗中重度肺部细菌感染的临床效果。方法选择我院2014年12月~2015年12月收治的84例中重度肺部细菌感染患者，按照治疗方法不同分为对照组和观察组。对照组患者接受头孢哌酮/舒巴坦治疗，观察组患者行头孢噻利治疗。观察两组患者治疗效果，并就两组患者细菌清除率和不良反应发生率进行比较。结果观察组患者的治疗总有效率明显优于对照组(<0.05)，且观察组患者的细菌清除率、不良反应发生率均显著优于对照组(<0.05)。结论头孢噻利治疗中重度肺部细菌感染的临床效果较好，不但能快速改善患者临床症状，且不良反应较少，细菌清除率高。%Objective To analyze the clinical effects of cefoselis and cefoperazone-sulbactam in the treatment of moderate and severe pulmonary bacterial infection.Methods 84 patients with moderate and severe pulmonary bacterial infection and who accepted treatments in our hospital from December,2014 to December,2015 were selected,and the patients were divided into control group and observation group according to the different treatment methods.In the control group,they were treated with the cefoperazone-sulbactam while in the observation group,they were treated with the cefoselis.Results The total effective rate in the observation group was significantly better than that in the control group ( <0.05),and the bacterial clearance rate and adverse reaction rate in the observation group was significantly better than those in the control group ( <0.05).Conclusion The cefoselis in the treatment of moderate and severe pulmonary bacterial infection are good,which only can improve the clinical symptoms of patients,and the adverse reaction is less,the rate of bacterial clearance is high.